Navigation Links
Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy

- Lesions non-invasively imaged in 5 to 10 minutes -

- Landmark Study Reported in Journal of Investigative Dermatology -

ROCHESTER, N.Y., Sept. 18 /PRNewswire/ -- A landmark publication that appeared in the Journal of Investigative Dermatology reports the results of a large, two site blinded clinical study. The paper is entitled "The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions."

The study, lead by Dr. Giovanni Pellacani, contained a total of 351 equivocal melanocytic lesions that were difficult for expert dermoscopists to diagnose. 136 of the 351 lesions were malignant melanomas. The highest sensitivity demonstrated by confocal microscopy was 96.3%. The highest accuracy corresponded to a sensitivity of 91.9% and a specificity of 69.3%. The standard of comparison for the study was biopsy of all 351 lesions, followed by traditional pathological examination.

"By giving reliable diagnostic information comparable to histology, confocal imaging represents the only feasible alternative to biopsy in the decision-making process faced by dermatologists examining melanocytic lesions," said Dr. Giovanni Pellacani, Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy, one of the world's leading in-vivo confocal imaging medical researchers. "Consequently, in vivo confocal microscopy is used at Modena and in several other melanoma clinics in Europe for the analysis of melanocytic lesions," Dr. Pellacani continued.

Images Acquired from Lucid VivaScopes(R) in 5 to 10 minutes

"The images in this study were acquired using VivaScope(R) confocal microscopes developed and manufactured by Lucid Inc., of Rochester, New York," said Jay Eastman, Ph.D., Chairman and CEO of Lucid, Inc. "This study represents a major clinical milestone in the transition of confocal imaging from a basic research tool to a diagnostic medical device being used routinely for evaluation of melanocytic lesions. Imaging a single lesion using the VivaScope(R) required just 5 to 10 minutes according to the authors," continued Eastman, "which makes it practical for everyday use in private dermatology practices worldwide."

Study Detailed in the Journal of Investigative Dermatology

The entire paper recounting the study can be found in the Journal of Investigative Dermatology (2007), 0, 000-000, doi: 10.1038/sj.jid.5700993, "The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions," authors Giovanni Pellacani, Pascale Guitera, Caterina Longo, Michelle Avramidis, Stefania Seidenari and Scott Menzies. On the Web, visit .

Authors Pellacani, Longo, and Seidenari are of the Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. Guitera, Avramidis, and Menzies are of the Faculty of Medicine, Sydney Melanoma Diagnostic Centre, Sydney Cancer Centre and Dermatology Department, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.

This paper builds on the results of an earlier pilot study that was published in the December 2005 issue of the Journal of the American Academy of Dermatology, beginning on page 979 of that issue.

About Lucid Inc.

Lucid Inc., based in Rochester, New York, USA, is a medical device and information company dedicated to creating innovative cellular imaging technology and using the Internet to securely deliver accurate, real-time VivaScope(R) cellular resolution images to medical professionals. When coupled with its digital VivaNet(TM) system, the company's ability to image in-vivo (living) tissue will aid medical practitioners and pathologists in skin cancer screening with clarity, speed and patient comfort. For more information about Lucid Inc., visit . Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jay Eastman, Ph.D.

SOURCE Lucid Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Urinalysis Analyzers: Large Capabilities in Every Size Device
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
6. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
7. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
8. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and GE ... an agreement for DILON to distribute GE,s Discovery NM750b ... globe. The signing of this distribution agreement will provide Dilon,s ... Breast Imaging system and is considered an initial step ... healthcare solutions for clinicians and their patients. ...
(Date:11/24/2015)... Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ... Breast Center a future-proof platform capable of expanding with the ... that Breast Center of Acadiana has entered into ... in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, ... Doug Godshall is scheduled to present at the ... December 1, 2015 at 3:00 p.m. ET.  The conference ... York . .  A ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... San Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... $15,000 in prizes were awarded to winners of the Create Real Impact awards. ... and creative expression to help stem the tide of distracted and reckless driving, the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... New patients who ... a referral for dental implants at her Mississauga, ON practice. Dr. Williams ... in the placement of dental implants. , Missing teeth can lead to a ...
Breaking Medicine News(10 mins):